期刊文献+

国际肺癌研究会分期项目--采用外科治疗的非小细胞肺癌的预后因素和病理TNM分期 被引量:20

The International Association for the Study of Lung Cancer Staging Project Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer
下载PDF
导出
摘要 目的本研究的目的是在国际肺癌研究协会国际分期数据库中采用外科治疗的I-IIIA期非小细胞肺癌病例中,评价除肿瘤原发灶、病理淋巴结和转移(TNM)分期外,细胞类型、年龄和性别的影响。材料和方法从提交至分期数据库的67725例非小细胞肺癌(NSCLC)病例中,筛选出9137例采用外科治疗的病例,这些病例的病理分期、年龄、性别和特殊组织细胞类型等信息均可获得。在亚组中分析记录行为状态和吸烟史。检验方法采用Cox比例风险回归和递归分割及合并(RPA)分析。结果病理TNM分期、年龄以及性别均为生存的独立预后因素。尽管细支气管肺泡癌(BAC)亚型间存在潜在的异质性,其相对于其它细胞类型仍具有生存优势。修正比较提示罹患鳞癌相对于非BAC腺癌及大细胞癌具有微弱的生存优势,尽管此优势仅限于男性患者。RPA结果提示TNM分期为首要因素,年龄是各分期分组的预后因素。在RPA分析中未发现细胞类型具有预后价值。依据RPA的结果形成预后分组,诸分组的预后价值得到北美监视、流行病学、结局结果注册机构的认可。在资料可得的亚组中,行为状态和吸烟史均为预后因素。在回归模型中,吸烟状态的纳入未影响其它变量的效果。结论年龄和性别已被证实为外科切除的非小细胞肺癌的重要预后因素。细胞类型的重要性次之,尽管归类于BAC的少部分病例相对于其它组织学类型具有生存优势,且鳞癌相对于非BAC腺癌具有微弱的生存优势。在未修正分析中,分期、年龄、性别和细胞类型间的不平衡可能会导致有关细胞类型的误导结果。在该分析中,病理TNM分类是最重要的预后因素。
出处 《中国肺癌杂志》 CAS 2010年第1期9-18,共10页 Chinese Journal of Lung Cancer
  • 相关文献

参考文献45

  • 1Goldstraw P, Crowley JJ; On behalf of the IASLC International Staging Project. The international association for the study of lung cancer international staging project on lung cancer. J Thorac Oncol 2006; 1:281-286.
  • 2Rami-Porta R, Ball D, Crowley JJ, et al. International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM cJassification for lung cancer. J Thorac Oncol 2007;2:593- 602.
  • 3Kusch VW, Crowley JJ, Giroux DJ, et al. International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM dassification for lung cancer. J Thorac Oncol 2007;2:603- 612.
  • 4Postmus PE, Brambilla E, Chansky K, et al. International Association for the Study of Lung Cancer International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC lung cancer staging project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007;2:686-693.
  • 5Goldstraw P, Crowley JJ, Chansky K, et al. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;8:706 - 714.
  • 6Sculier Jp, Chansky K, CrowleyJJ, et al. International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. J Thorac Oncol 2008;3:4,57- 466.
  • 7Groome PA, Bolejack V, Crowley JJ, et al. IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694 -705.
  • 8Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological Typing of Lung and Pleural Tumors, 3rd Ed. Berlin: Springer, 1999.
  • 9Crowley JJ, Leblanc M, Jacobson J, Salmon S. Some Exploratory Tools for Survival Analysis. In Lin DY, Fleming TR, (Eds.), New York: Springer, 1997.
  • 10Cancer Statistics Branch Surveillance Program DCCPS. The SEEK Program Code Manual, 3rd Ed. Bethesda, MD: National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Department of Health and Human Services, 1998.

同被引文献184

  • 1王方,徐文艳,刘莉,任秀红,刘平平,郑力,张浩,张松松,许亚茹,郭振兴.初诊恶性实体肿瘤患者贫血的影响因素[J].武警医学,2021,32(8):702-706. 被引量:3
  • 2陈名声,徐焰,郝晓柯,张永生,徐威,卢宝弼.血清性激素的水平对男性肺癌患者诊断的意义[J].中国肺癌杂志,2005,8(4):300-303. 被引量:11
  • 3Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortal- ity in the United States, 1930-1998. Cancer, 2003, 97( 12 Suppl): 3133-3275.
  • 4Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? Lung Cancer, 2002, 38 (Suppl 2): S45-S50.
  • 5中国抗癌协会肺癌专业委员会编著.2010中国肺癌临床指南.第1版.北京:人民卫生出版社,2010.7.
  • 6Meriggi F, Zaniboni A. Non-small-cell lung cancer in the elderly. Crit Rev Oncol Hematol, 2006, 57(2): 183-190.
  • 7Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Nail Cancer Inst, 2002, 94(3): 173-181.
  • 8Wakelee HA, Wang W, Schiller JH, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol, 2006, 1 (S): 441-446.
  • 9Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cis- platin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer, 2005, 104(12): 2766-2774.
  • 10Kefeli U, Kaya S, Ustaalioglu BO, et al. Prognostic factors in elderly patients with non-small cell lung cancer: a two-center experience. Med Oncol, 2010 Mar 31. [Epub ahead of print].

引证文献20

二级引证文献97

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部